PPT-SW GLH services for NSCLC – An update

Professor Rachel Butler The genomic complexity of advanced NSCLC Jordan et al Cancer Discovery 2017 gt50 NSCLC now have actionable variant Treatment algorithm NHSE National Genomic Test Directory. Brada. . Torino. . 6 March 2015. Perspectives in lung cancer. . Stereotactic ablative radiation therapy (. SABR). in patients with inoperable NSCLC. SABR in the context of modern radiotherapy of . Gandara. , MD. University of California, Davis . Comprehensive Cancer Center. Biomarker-driven Phase III Clinical Trials: . Practical . & . Design Considerations. Clinical trial . d. esigns that define the. Le Chevalier, . MD. The Role of Translational Research . in . NSCLC. Outline of Talk. The importance of translational research in improving treatment of NSCLC. Key remaining unmet needs. Overview of promising approaches/agents in the future treatment of NSCLC . Renato G. Martins, MD, MPH. Medical Director, Thoracic/Head and Neck; General Oncology and Hematology. Seattle Cancer Care Alliance. July 28, 2015. 11:30 am – 12:30 pm, EST. ICLIO e-Course 02. Objectives. MD. The Evolving Treatment Landscape in NSCLC: Congress Updates. Outline of Talk. Provide a brief overview of current advances in the treatment of NSCLC. EGFR-targeted agents . ALK-EML4 targeted agents . Uzma Rani . Locality Manager, Derby Advanced Commissioning Locality. Clinical Commissioning Group. Southern Derbyshire . Preparing for Authorisation. . - 1. st. October 2012 application. . - 360 Stakeholder survey. Jared Weiss, MD . Assistant . Professor of Medicine . Division . of Hematology and Oncology . University . of North Carolina School of Medicine . Attending Physician. UNC . Lineberger. Comprehensive Cancer . The Coming Paradigm Shift. Faculty. Suresh S. Ramalingam, MD. Professor of Hematology/Oncology . Director, Lung . Cancer Program . Winship Cancer Institute. Emory University. Atlanta, . Georgia. Program Goals. Dr Tan . Jiunn. Liang. Clinical Specialist (Respiratory Medicine). Department of Medicine. Universiti. Malaya Medical Centre. Disclaimer. This program is provided as a service to the medical profession and represents the opinions of the speakers, not necessarily those of Merck or MSD or its affiliates. The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature Manel Esteller , MD, PhD. Director, Josep Carreras Leukaemia Research Institute (IJC) Director, Cancer Epigenetics and Biology Program (PEBC) actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Disclosures for . Dr. Langer. Advisory Committee. Abbott Laboratories, AstraZeneca Pharmaceuticals LP, . proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Moderator. Neil Love, MD. Faculty . Oncology Grand Rounds. . Emerging Strategies in Non-Small Cell Lung Cancer. Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum. Friday, October 11, 2019. 6:15 PM – 7:45 PM . Chicago, Illinois. Faculty. . Moderator. Joel W Neal, MD, PhD. Nasser H Hanna, MD. Intervista a Federico . Cappuzzo. Background:. Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) is associated with OS, PFS and ORR in pts with advanced NSCLC treated with atezolizumab (anti-PDL1, MPDL3280A; Spigel et al, Spira et al, ASCO 2015), indicating that PD-L1 expression on both TC and IC is important for anti-tumor immunity. However, these 2 distinct expression patterns suggest the existence of previously unidentified NSCLC subtypes with distinct immunologic profiles. .